Martin V Ton, MD | |
600 Gresham Dr, Norfolk, VA 23507-1904 | |
(757) 668-3871 | |
Not Available |
Full Name | Martin V Ton |
---|---|
Gender | Male |
Speciality | Pain Management |
Experience | 35 Years |
Location | 600 Gresham Dr, Norfolk, Virginia |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1316966427 | NPI | - | NPPES |
5709172 | Medicaid | VA | |
5710120 | Medicaid | VA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207L00000X | Anesthesiology | (Virginia) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Sentara Virginia Beach General Hospital | Virginia beach, VA | Hospital |
Sentara Princess Anne Hospital | Virginia beach, VA | Hospital |
Sentara Leigh Hospital | Norfolk, VA | Hospital |
Sentara Norfolk General Hospital | Norfolk, VA | Hospital |
Entity Name | Consultants In Pain Management Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1366545154 PECOS PAC ID: 1951325950 Enrollment ID: O20060118000331 |
News Archive
A new University of Utah study is the first to provide clear insight into contributors to suicide risk among military personnel and veterans who have deployed.
Varying severity of COVID-19 symptoms in patients is reflected by levels of a chemical biomarker in their body which scientists say could be used to better manage treatments and other interventions, including vaccinations.
Veran Medical Technologies announced today that it has recently received two clearances (K093146 & K093995) from the U.S. Food and Drug Administration (FDA) to expand its indications for use of the ig4 Navigation platform.
Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) carrying the ALK (anaplastic lymphoma kinases) fusion gene, who have progressed on one prior treatment with a platinum-based chemotherapy.
› Verified 8 days ago
Entity Name | Consultants In Pain Medicine |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1699872481 PECOS PAC ID: 7416140132 Enrollment ID: O20101026000415 |
News Archive
A new University of Utah study is the first to provide clear insight into contributors to suicide risk among military personnel and veterans who have deployed.
Varying severity of COVID-19 symptoms in patients is reflected by levels of a chemical biomarker in their body which scientists say could be used to better manage treatments and other interventions, including vaccinations.
Veran Medical Technologies announced today that it has recently received two clearances (K093146 & K093995) from the U.S. Food and Drug Administration (FDA) to expand its indications for use of the ig4 Navigation platform.
Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) carrying the ALK (anaplastic lymphoma kinases) fusion gene, who have progressed on one prior treatment with a platinum-based chemotherapy.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Martin V Ton, MD 134 Business Park Dr, Virginia Beach, VA 23462-6523 Ph: (757) 473-0055 | Martin V Ton, MD 600 Gresham Dr, Norfolk, VA 23507-1904 Ph: (757) 668-3871 |
News Archive
A new University of Utah study is the first to provide clear insight into contributors to suicide risk among military personnel and veterans who have deployed.
Varying severity of COVID-19 symptoms in patients is reflected by levels of a chemical biomarker in their body which scientists say could be used to better manage treatments and other interventions, including vaccinations.
Veran Medical Technologies announced today that it has recently received two clearances (K093146 & K093995) from the U.S. Food and Drug Administration (FDA) to expand its indications for use of the ig4 Navigation platform.
Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) carrying the ALK (anaplastic lymphoma kinases) fusion gene, who have progressed on one prior treatment with a platinum-based chemotherapy.
› Verified 8 days ago
Kenneth F. Tiffany, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 601 Childrens Ln, Norfolk, VA 23507 Phone: 757-668-7456 Fax: 757-668-9255 | |
Ross H Zoll, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 600 Gresham Dr, Norfolk, VA 23507 Phone: 757-668-3871 | |
Steven C Johnson, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 600 Gresham Dr, Norfolk, VA 23507 Phone: 757-668-3871 | |
Dr. Valbona Kanarek, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 811 Redgate Ave, Norfolk, VA 23507 Phone: 757-668-7007 Fax: 757-668-8658 | |
Kelli A Petronis, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 601 Childrens Ln, Norfolk, VA 23507 Phone: 757-668-9222 Fax: 757-668-7568 | |
Allan E Stiner, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 600 Gresham Dr, Norfolk, VA 23507 Phone: 757-668-3871 | |
Destiny Fenger Chau, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 601 Childrens Ln, Norfolk, VA 23507 Phone: 757-668-7320 Fax: 757-668-9735 |